InspireMD Recalls CGuard Prime Delivery System, Withdraws 2026 Revenue Guidance Amidst Going Concern Warning
NSPR sits 33% above its 52-week low of $1.12 on elevated volume (46× avg).
Summary
InspireMD initiated a voluntary recall of its CGuard Prime 135 cm delivery system due to performance issues and consequently withdrew its full-year 2026 revenue guidance, while also announcing FDA IDE approval for a new pivotal study.
Key Events · Product Development and Regulatory · NSPR
-
Voluntary Product Recall Initiated
InspireMD initiated a voluntary recall in the U.S. for its CGuard® Prime 135 cm carotid stent delivery system after determining it did not meet performance expectations during a controlled launch. This recall does not include the CGuard stent implant itself.
-
Full-Year 2026 Revenue Guidance Withdrawn
Concurrent with the recall, the company withdrew its prior full-year 2026 revenue guidance, citing the impact of the temporary discontinuation of commercial activity in the U.S. pending anticipated FDA approval of its original CGuard stent delivery system.
-
FDA IDE Approved for New Pivotal Study
The U.S. Food and Drug Administration (FDA) approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system (NPS) for use in transcarotid artery revascularization (TCAR) procedures.
-
Anticipated FDA Approvals for Other Products
InspireMD anticipates FDA approval for its original CGuard stent delivery system for CAS procedures in the U.S. in Q3 2026 and for its CGuard Prime 80 cm for TCAR procedures in 2H 2026. Design improvements for the recalled CGuard Prime 135 cm are expected to receive FDA approval in H1 2027.
Analysis · NSPR · Industrial Applications And Services
InspireMD's voluntary recall of its CGuard Prime 135 cm delivery system and subsequent withdrawal of full-year 2026 revenue guidance are significant negative developments. This directly impacts the company's near-term financial performance and operational stability, especially given its existing 'going concern' warning. While the FDA approval for the CGUARDIANS III pivotal study for SwitchGuard NPS is a positive long-term pipeline development, it is overshadowed by the immediate operational setback and financial uncertainty. Investors should monitor the company's Q1 2026 earnings call for further details on the financial impact and remediation plans.
At the time of this filing, NSPR was trading at $1.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $53.9M. The 52-week trading range was $1.12 to $2.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.